Melanotic neuroectodermal tumor of infancy and fetal hydantoin syndrome.
Fetal hydantoin syndrome (FHS), a characteristic pattern of altered growth and development, has been well described in recent years in offsprings of epileptic mothers taking phenytoin or other hydantoin anticonvulsants during the gestational period. Recent reports of neuroblastoma in three patients with the FHS further raise the questions of the "oncogenic effect " of hydantoin compounds. A case of melanotic neuroectodermal tumor of infancy (MNTI) has been studied clinically and pathologically including light microscopy, histochemistry, and electron microscopy. This case strengthens the evidence for the teratogenic and oncogenic effects of hydantoin compounds and we believe that it represents the first reported case of FHS associated with MNTI. It would be most important from a clinical standpoint to carefully scrutinize individuals with the FHS for neoplasias. Furthermore, detailed gestational drug history in children with neuroblastoma and other neoplasias should be carefully searched for, with the hope of clarifying the definitive oncogenic effect of hydantoin compounds.
D000014:Abnormalities, Drug-Induced / Q000150:complications; D002610:Cheek; D003394:Craniofacial Dysostosis / Q000139:chemically induced* / Q000150:complications; D005153:Facial Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects*; D007223:Infant; D008297:Male; D008431:Maternal-Fetal Exchange; D009373:Neoplasms, Germ Cell and Embryonal / Q000150:complications* / Q000473:pathology / Q000628:therapy; D011247:Pregnancy; D013577:Syndrome
D006827:Hydantoins